Topline Phase 3 results show Eli Lilly’s retatrutide beat Novo’s Ozempic on measures of blood sugar and weight loss in adults with type 2 diabetes. Retatrutide is a peptide designed to activate three metabolic targets versus just one hit by Ozempic. The post Eli Lilly’s ‘Triple-G’ Drug Tops Ozempic in Head-to-Head Type 2 Diabetes Trial appeared first on MedCity News.

With healthcare affordability set to influence voters’ decisions in next week’s midterm elections, the Healthcare Financial Management Association is calling on healthcare leaders to move beyond finger-pointing and work together to address rising costs. HFMA is urging financial leaders across healthcare to sign its Declaration on Healthcare Affordability and Sustainability. The post Ahead of Midterms, HFMA Calls for Cross-Sector Action on Healthcare Affordability appeared first on MedCity News.

By using existing data to better understand members and implementing retention strategies, plans can remain sustainable and members can get the care they need. The post Work Requirements Put New Pressure On Medicaid Member Retention appeared first on MedCity News.

[Sponsored] A webinar sponsored by Inovalon explored how hospitals and pharmacies can work together to generate the best outcomes for patients while improving patient safety. The post How Can Hospitals and Pharmacists Collaborate on Effective Stewardship Programs for Opioids and Antibiotics? appeared first on MedCity News.

Willow Innovations acquired Swehl and Momtech to expand its maternal health offerings beyond breast pumps. The post Willow Acquires 2 Women’s Health Companies appeared first on MedCity News.

Artiva Biotherapeutics attributed one of the fatalities to a drug used to prepare patients for cell therapy and not to the cell therapy itself. But Artiva’s setbacks follow safety signals reported for autoimmune disease cell therapy programs from Novartis and Bristol Myers Squibb. The post Patient Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva appeared first on MedCity News.

As health plans grapple with new federal deadlines for prior authorization decisions, healthcare AI startup ClarityCare has raised $16.5 million to automate the administrative workload that can keep patients waiting for the care they need. The post ClarityCare Raises $16.5M to Speed Up Prior Authorizations  appeared first on MedCity News.

The cost of waiting is not evenly distributed. Rural and critical access hospitals report under 50 percent adoption of even basic predictive tools, compared with 86 percent among top-tier system-affiliated hospitals. Every year without a bridge widens that gap, and it widens it fastest for the hospitals with the least room to absorb it. The post A Market, Not a Mandate, Is the Fastest Way to Bring AI Into Hospitals appeared first on MedCity News.

Women’s health experts had mixed reactions to the Trump administration’s executive order on women’s health. The post How Experts Are Reacting to Trump’s Women’s Health Executive Order appeared first on MedCity News.

Corxel Pharmaceuticals is catching up to others with oral GLP-1 obesity drugs, but the biotech claims its small molecule could offer better tolerability compared to the rest of its class. The SPAC merger taking Corxel public is expected to close in the first half of 2027, which is when the biotech plans to start a Phase 3 trial. The post Obesity Biotech Corxel Is Going Public in a Merger as Oral GLP-1 Heads to Phase 3 appeared first on MedCity News.

Sutter Health, a nonprofit healthcare system based in Sacramento, California, is expanding its digital chronic disease management program, Sutter Sync, to include patients with heart failure. The expansion adds a remote monitoring technology from San Francisco-based medical tech company Bodyport. The program expansion comes as health systems look for ways to identify deterioration in a low acuity environment before patients reach the point of needing emergency hospitalization. The post Sutter Health Expands Remote Monitoring Program to Patients with Heart Failure appeared first on MedCity News.

CMS has introduced uncertainty about whether Medicare will participate in that modernization or preserve the old system under a different name. The consequences extend far beyond billing The post In a Maternity Care Crisis, CMS Undermines Efforts To Modernize Care appeared first on MedCity News.

[Sponsored] For US biotech companies developing rare disease therapies, decisions about clinical evidence, patient populations and regulatory advice can have consequences in Europe long before a marketing application is submitted. The post FDA Alignment Is a Starting Point, Not a Rare Disease Strategy for the European Market appeared first on MedCity News.

CareValidate expanded its HRT offering for telehealth companies, combining hormone therapy with provider access, pharmacy services and AI-powered care coordination. The post CareValidate Launches Expanded HRT Offering appeared first on MedCity News.

Lycia Therapeutics’ protein-degrading drugs are based on the research of Carolyn Bertozzi, a Stanford chemistry professor and Nobel laureate. Lycia’s lead drug candidate is in development for food allergy, where it could compete against the blockbuster Roche drug Xolair. The post Lycia Lands a $317M IPO for Inflammation Drugs Based on Nobel Prize-Winning Science appeared first on MedCity News.